Affinium Pharmaceuticals announces completion of recruitment for Phase 2 clinical trial of AFN-1252
- Details
- Category: Clinical Trials
Affinium Pharmaceuticals announced that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").
Long-term efficacy and tolerability of Vimpat® (lacosamide)
- Details
- Category: Clinical Trials
UCB's antiepileptic drug (AED) Vimpat® (lacosamide) featured in several studies and analyses presented at the 62nd annual American Academy of Neurology (AAN) meeting. These data offer additional clinical evidence supporting the use of lacosamide as adjunctive therapy in the treatment of adult patients with partial-onset seizures.
Anavex comments on failure of Pfizer and Medivation's Alzheimer's Investigational drug Dimebon
- Details
- Category: Clinical Trials
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) issued a statement following the announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.
Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of Cariprazine
- Details
- Category: Clinical Trials

Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations
- Details
- Category: Clinical Trials

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Details
- Category: Clinical Trials

HemCon Medical Technologies, Inc. Announces Improved Results from Live Nail Infection Study
- Details
- Category: Clinical Trials
HemCon has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology.
More Pharma News ...
- Encouraging results support further development of Almirall's long-acting beta-agonist (LABA)
- Anavex completes successful preclinical studies on lead Alzheimer's drug candidate
- Results from phase 2b "DEEP" study in severe pre-eclampsia
- Cleviprex(TM) Demonstrated Rapid, Precise Blood Pressure Control in High-Risk Patients
- Pharmion and MethylGene Present Favorable Clinical Data
- Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
- Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer